PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT06616532
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital Of Ningbo University, Ningbo, Zhejiang, China
A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
- Conditions
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06584071
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06419621
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical University, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of PM1015 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05950815
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05918133
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
PM8002 in the Treatment of Patients With Advanced Solid Tumors
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT05918445
- Locations
- 🇨🇳
Shanghai Orient Hospital, Shanghai, Shanghai, China
🇨🇳Baoji Central Hospital, Baoji, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05918107
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT05879068
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, China
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05879055
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Fujian Province Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
A Study of PM1022 in Patients With Advanced Tumors
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05867771
- Locations
- 🇨🇳
Yan Zhang, Jinan, Shandong, China
🇨🇳Ye Guo, Shanghai, China